Catalyst Pharmaceuticals CPRX announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters guide for this Monday's Q2 earnings announcement.
Earnings and Revenue
Wall Street analysts see Catalyst Pharmaceuticals reporting earnings of $0.08 per share on sales of $29.48 million. In the same quarter last year, Catalyst Pharmaceuticals reported earnings per share of $0.1 on sales of $28.84 million. If the company were to report in-line earnings when it publishes results Monday, earnings would be down 20.0%. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.09 | 0.10 | 0.11 | 0.02 |
| EPS Actual | 0.10 | 0.07 | 0.13 | 0.10 |
| Revenue Estimate | 31.46 M | 29.40 M | 33.18 M | 18.49 M |
| Revenue Actual | 29.14 M | 30.12 M | 30.90 M | 28.84 M |
Stock Performance
Over the last 52-week period, shares are down 17.68%. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Catalyst Pharmaceuticals is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/cprx/mediaframe/39672/indexl.html
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
